PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07K 14/29, C12N 15/86, A61K 31/70

A1

(11) International Publication Number: **WO 98/16554**

(43) International Publication Date: 23 April 1998 (23.04.98)

(21) International Application Number: PCT/US97/19044

(22) International Filing Date: 17 October 1997 (17.10.97)

(30) Priority Data:
08/733,230 17 October 1996 (17.10.96) US

(71) Applicant: UNIVERSITY OF FLORIDA [US/US]; 223 Grinter Hall, Gainesville, FL 32611 (US).

(72) Inventors: BARBET, Anthony, F.; 8803 S.W. 138th Street, Archer, FL 32618 (US). GANTA, Roman, Reddy; 6519 West Newberry Road #802, Gainesville, FL 32605 (US). MCGUIRE, Travis, C.; S.W. 920 Crestview, Pullman, WA 99163 (US). BURRIDGE, Michael, J.; 10021 S.W. 67th Drive, Gainesville, FL 32608 (US). NYIKA, Aceme; House 6282, Unit J, Chitungwiza, Harare (ZW). RURANGIRWA, Fred, R.; 2065 N.W. Turner Drive, Pullman, WA 99163 (US). MAHAN, Suman, M.; 71 Olwyn Avenue, Strathaven, Harare (ZW).

(74) Agents: SALIWANCHIK, David, R. et al.; Saliwanchik, Lloyd & Saliwanchik, Suite A-1, 2421 N.W. 41st Street, Gainesville, FL 32606-6669 (US).

(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SD, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NUCLEIC ACID VACCINES AGAINST RICKETTSIAL DISEASES AND METHODS OF USE

(57) Abstract

Described are nucelic acid vaccines containing genes to protect animals or humans against rickettsial diseases. Also described are polypeptides and methods of using these polypeptides to detect antibodies to pathogens.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

DESCRIPTION

NUCLEIC ACID VACCINES AGAINST RICKETTSIAL DISEASES AND METHODS OF USE

This invention was made with government support under USAID Grant No. LAG-1328-G-00-3030-00. The government has certain rights in this invention.

Cross-Reference to a Related Application

This is a continuation-in-part of U.S. patent application Serial No. 08/733,230, filed October 17, 1996.

Technical Field

This invention relates to nucleic acid vaccines for rickettsial diseases of animals, including humans.

Background of the Invention

The rickettsias are a group of small bacteria commonly transmitted by arthropod vectors to man and animals, in which they may cause serious disease. The pathogens causing human rickettsial diseases include the agent of epidemic typhus, *Rickettsia prowazekii*, which has resulted in the deaths of millions of people during wartime and natural disasters. The causative agents of spotted fever, *e.g.*, *Rickettsia rickettsii* and *Rickettsia conorii*, are also included within this group. Recently, new types of human rickettsial disease caused by members of the tribe *Ehrlichiae* have been described. *Ehrlichiae* infect leukocytes and endothelial cells of many different mammalian species, some of them causing serious human and veterinary diseases. Over 400 cases of human ehrlichiosis, including some fatalities, caused by *Ehrlichia chaffeensis* have now been reported. Clinical signs of human ehrlichiosis are similar to those of Rocky Mountain spotted fever, including fever, nausea, vomiting, headache, and rash.

Heartwater is another infectious disease caused by a rickettsial pathogen, namely *Cowdria ruminantium*, and is transmitted by ticks of the genus *Amblyomma*. The disease occurs throughout most of Africa and has an estimated endemic area of about 5 million square miles. In endemic areas, heartwater is a latent infection in indigenous breeds of cattle that have been subjected to centuries of natural selection. The problems occur where the disease contacts susceptible or naive cattle and other ruminants. Heartwater has been confirmed to be on the

island of Guadeloupe in the Caribbean and is spreading through the Caribbean Islands. The tick vectors responsible for spreading this disease are already present on the American mainland and threaten the livestock industry in North and South America.

In acute cases of heartwater, animals exhibit a sudden rise in temperature, signs of anorexia, cessation of rumination, and nervous symptoms including staggering, muscle twitching, and convulsions. Death usually occurs during these convulsions. Peracute cases of the disease occur where the animal collapses and dies in convulsions having shown no preliminary symptoms. Mortality is high in susceptible animals. Angora sheep infected with the disease have a 90% mortality rate while susceptible cattle strains have up to a 60% mortality rate.

If detected early, tetracycline or chloramphenicol treatment are effective against rickettsial infections, but symptoms are similar to numerous other infections and there are no satisfactory diagnostic tests (Helmick, C., K. Bernard, L. D'Angelo [1984] *J. Infect. Dis.* 150:480).

Animals which have recovered from heartwater are resistant to further homologous, and in some cases heterologous, strain challenge. It has similarly been found that persons recovering from a rickettsial infection may develop a solid and lasting immunity. Individuals recovered from natural infections are often immune to multiple isolates and even species. For example, guinea pigs immunized with a recombinant *R. conorii* protein were partially protected even against *R. rickettsii* (Vishwanath, S., G. McDonald, N. Watkins [1990] *Infect. Immun.* 58:646). It is known that there is structural variation in rickettsial antigens between different geographical isolates. Thus, a functional recombinant vaccine against multiple isolates would need to contain multiple epitopes, *e.g.*, protective T and B cell epitopes, shared between isolates. It is believed that serum antibodies do not play a significant role in the mechanism of immunity against rickettsia (Uilenberg, G. [1983] *Advances in Vet. Sci. and Comp. Med.* 27:427-480; Du Plessis, Plessis, J.L. [1970] *Onderstepoort J. Vet. Res.* 37(3):147-150).

Vaccines based on inactivated or attenuated rickettsiae have been developed against certain rickettsial diseases, for example against *R. prowazekii* and *R. rickettsii*. However, these vaccines have major problems or disadvantages, including undesirable toxic reactions, difficulty in standardization, and expense (Woodward, T. [1981] "Rickettsial diseases: certain unsettled problems in their historical perspective," In *Rickettsia and Rickettsial Diseases*, W. Burgdorfer and R. Anacker, eds., Academic Press, New York, pp. 17-40).

A vaccine currently used in the control of heartwater is composed of live infected sheep blood. This vaccine also has several disadvantages. First, expertise is required for the

intravenous inoculation techniques required to administer this vaccine. Second, vaccinated animals may experience shock and so require daily monitoring for a period after vaccination. There is a possibility of death due to shock throughout this monitoring period, and the drugs needed to treat any shock induced by vaccination are costly. Third, blood-borne parasites may be present in the blood vaccine and be transmitted to the vaccinates. Finally, the blood vaccine requires a cold chain to preserve the vaccine.

Clearly, a safer, more effective vaccine that is easily administered would be particularly advantageous. For these reasons, and with the advent of new methods in biotechnology, investigators have concentrated recently on the development of new types of vaccines, including recombinant vaccines. However, recombinant vaccine antigens must be carefully selected and presented to the immune system such that shared epitopes are recognized. These factors have contributed to the search for effective vaccines.

A protective vaccine against rickettsiae that elicits a complete immune response can be advantageous. A few antigens which potentially can be useful as vaccines have now been identified and sequenced for various pathogenic rickettsia. The genes encoding the antigens and that can be employed to recombinantly produce those antigen have also been identified and sequenced. Certain protective antigens identified for *R. rickettsii*, *R. conorii*, and *R. prowazekii* (*e.g.*, rOmpA and rOmpB) are large (>100 kDa), dependent on retention of native conformation for protective efficacy, but are often degraded when produced in recombinant systems. This presents technical and quality-control problems if purified recombinant proteins are to be included in a vaccine. The mode of presentation of a recombinant antigen to the immune system can also be an important factor in the immune response.

Nucleic acid vaccination has been shown to induce protective immune responses in non-viral systems and in diverse animal species (Special Conference Issue, WHO meeting on nucleic acid vaccines [1994] *Vaccine* 12:1491). Nucleic acid vaccination has induced cytotoxic lymphocyte (CTL), T-helper 1, and antibody responses, and has been shown to be protective against disease (Ulmer, J., J. Donelly, S. Parker *et al.* [1993] *Science* 259:1745). For example, direct intramuscular injection of mice with DNA encoding the influenza nucleoprotein caused the production of high titer antibodies, nucleoprotein-specific CTLs, and protection against viral challenge. Immunization of mice with plasmid DNA encoding the *Plasmodium yoelii* circumsporozoite protein induced high antibody titers against malaria sporozoites and CTLs, and protection against challenge infection (Sedegah, M., R. Hedstrom, P. Hobart, S. Hoffman [1994] *Proc. Natl. Acad. Sci. USA* 91:9866). Cattle immunized with plasmids encoding bovine herpesvirus 1 (BHV-1) glycoprotein IV developed neutralizing antibody and were partially

protected (Cox, G., T. Zamb, L. Babiuk [1993] *J. Virol.* 67:5664). However, it has been a question in the field of immunization whether the recently discovered technology of nucleic acid vaccines can provide improved protection against an antigenic drift variant. Moreover, it has not heretofore been recognized or suggested that nucleic acid vaccines may be successful to protect against rickettsial disease or that a major surface protein conserved in rickettsia was protective against disease.

Brief Summary of the Invention

Disclosed and claimed here are novel vaccines for conferring immunity to rickettsia infection, including *Cowdria ruminantium* causing heartwater. Also disclosed are novel nucleic acid compositions and methods of using those compositions, including to confer immunity in a susceptible host. Also disclosed are novel materials and methods for diagnosing infections by *Ehrlichia* in humans or animals.

One aspect of the subject invention concerns a nucleic acid, *e.g.*, DNA or mRNA, vaccine containing the major antigenic protein 1 gene (MAP1) or the major antigenic protein 2 gene (MAP2) of rickettsial pathogens. In one embodiment, the nucleic acid vaccines can be driven by the human cytomegalovirus (HCMV) enhancer-promoter. In studies immunizing mice by intramuscular injection of a DNA vaccine composition according to the subject invention, immunized mice seroconverted and reacted with MAP1 in antigen blots. Splenocytes from immunized mice, but not from control mice immunized with vector only, proliferated in response to recombinant MAP1 and rickettsial antigens in *in vitro* lymphocyte proliferation tests. In experiments testing different DNA vaccine dose regimens, increased survival rates as compared to controls were observed on challenge with rickettsia. Accordingly, the subject invention concerns the discovery that DNA vaccines can induce protective immunity against rickettsial disease or death resulting therefrom.

Brief Description of the Drawings

Figures 1A-1C show a comparison of the amino acid sequences from alignment of the three rickettsial proteins, namely, *Cowdria ruminantium* (*C.r.*), *Ehrlichia chaffeensis* (*E.c.*), and *Anaplasma marginale* (*A.m.*).

Figures 2A-2C shows the DNA sequence of the 28 kDa gene locus cloned from *E. chaffeensis* (Fig. 2A-2B) and *E. canis* (Fig. 2C). One letter amino acid codes for the deduced protein sequences are presented below the nucleotide sequence. The proposed sigma-70-like promoter sequences (38) are presented in bold and underlined text as -10 and -35 (consensus -35

and -10 sequences are TTGACA and TATAAT, respectively). Similarly, consensus ribosomal binding sites and transcription terminator sequences (bold letter sequence) are identified. G-rich regions identified in the *E. chaffeensis* sequence are underlined. The conserved sequences from within the coding regions selected for RT-PCR assay are identified with italics and underlined text.

Figure 3A shows the complete sequence of the MAP2 homolog of *Ehrlichia canis*. The arrow (➞) represents the predicted start of the mature protein. The asterisk (*) represents the stop codon. Underlined nucleotides 5' to the open reading frame with -35 and -10 below represent predicted promoter sequences. Double underlined nucleotides represent the predicted ribosomal binding site. Underlined nucleotides 3' to the open reading frame represent possible transcription termination sequences.

Figure 3B shows the complete sequence of the MAP2 homolog of *Ehrlichia chaffeensis*. The arrow (➞) represents the predicted start of the mature protein. The asterisk (*) represents the stop codon. Underlined nucleotides 5' to the open reading frame with -35 and -10 below represent predicted promoter sequences. Double underlined nucleotides represent the predicted ribosomal binding site. Underlined nucleotides 3' to the open reading frame represent possible transcription termination sequences.

Brief Description of the Sequences

SEQ ID NO. 1 is the coding sequence of the MAP1 gene from *Cowdria ruminantium* (Highway isolate).

SEQ ID NO. 2 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 1.

SEQ ID NO. 3 is the coding sequence of the MAP1 gene from *Ehrlichia chaffeensis*.

SEQ ID NO. 4 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 3.

SEQ ID NO. 5 is the *Anaplasma marginale* MSP4 gene coding sequence.

SEQ ID NO. 6 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 5.

SEQ ID NO. 7 is a partial coding sequence of the VSA1 gene from *Ehrlichia chaffeensis*, also shown in Figures 2A-2B.

SEQ ID NO. 8 is the coding sequence of the VSA2 gene from *Ehrlichia chaffeensis*, also shown in Figures 2A-2B.

SEQ ID NO. 9 is the coding sequence of the VSA3 gene from *Ehrlichia chaffeensis*, also shown in Figures 2A-2B.

SEQ ID NO. 10 is the coding sequence of the VSA4 gene from *Ehrlichia chaffeensis*, also shown in Figures 2A-2B.

SEQ ID NO. 11 is a partial coding sequence of the VSA5 gene from *Ehrlichia chaffeensis*, also shown in Figures 2A-2B.

SEQ ID NO. 12 is the coding sequence of the VSA1 gene from *Ehrlichia canis*, also shown in Figure 2C.

SEQ ID NO. 13 is a partial coding sequence of the VSA2 gene from *Ehrlichia canis*, also shown in Figure 2C.

SEQ ID NO. 14 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 7, also shown in Figures 2A-2B.

SEQ ID NO. 15 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 8, also shown in Figures 2A-2B.

SEQ ID NO. 16 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 9, also shown in Figures 2A-2B.

SEQ ID NO. 17 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 10, also shown in Figures 2A-2B.

SEQ ID NO. 18 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 11, also shown in Figures 2A-2B.

SEQ ID NO. 19 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 12, also shown in Figure 2C.

SEQ ID NO. 20 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 13, also shown in Figure 2C.

SEQ ID NO. 21 is the coding sequence of the MAP2 gene from *Ehrlichia canis*, also shown in Figure 3A.

SEQ ID NO. 22 is the coding sequence of the MAP2 gene from *Ehrlichia chaffeensis*, also shown in Figure 3B.

SEQ ID NO. 23 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 21, also shown in Figure 3A.

SEQ ID NO. 24 is the polypeptide encoded by the polynucleotide of SEQ ID NO. 22, also shown in Figure 3B.

Detailed Disclosure of the Invention

In one embodiment, the subject invention concerns a novel strategy, termed nucleic acid vaccination, for eliciting an immune response protective against rickettsial disease. The subject invention also concerns novel compositions that can be employed according to this novel strategy for eliciting a protective immune response. According to the subject invention,

recombinant plasmid DNA or mRNA encoding an antigen of interest is inoculated directly into the human or animal host where the antigen is expressed and an immune response induced. Advantageously, problems of protein purification, as can be encountered with antigen delivery using live vectors, can be virtually eliminated by employing the compositions or methods according to the subject invention. Unlike live vector delivery, the subject invention can provide a further advantage in that the DNA or RNA does not replicate in the host, but remains episomal with gene expression directed for as long as 19 months or more post-injection. See, for example, Wolff, J.A., J.J. Ludike, G. Acsadi, P. Williams, A. Jani (1992) *Hum. Mol. Genet.* 1:363. A complete immune response can be obtained as recombinant antigen is synthesized intracellularly and presented to the host immune system in the context of autologous class I and class II MHC molecules.

In one embodiment, the subject invention concerns nucleic acids and compositions comprising those nucleic acids that can be effective in protecting an animal from disease or death caused by rickettsia. For example, a nucleic acid vaccine of the subject invention has been shown to be protective against *Cowdria ruminantium*, the causative agent of heartwater in domestic ruminants. Accordingly, DNA sequences of rickettsial genes, *e.g.*, MAP1 or homologues thereof, can be used as nucleic acid vaccines against human and animal rickettsial diseases. The MAP1 gene used to obtain this protection is also present in other rickettsiae including *Anaplasma marginale*, *Ehrlichia canis*, and in a causative agent of human ehrlichiosis, *Ehrlichia chaffeensis* (van Vliet, A., F. Jongejan, M. van Kleef, B. van der Zeijst [1994] *Infect. Immun.* 62:1451). The MAP1 gene or a MAP1-like gene can also be found in certain *Rickettsia* spp. MAP1-like genes from *Ehrlichia chaffeensis* and *Ehrlichia canis* have now been cloned and sequenced. These MAP-1 homologs are also referred to herein as Variable Surface Antigen (VSA) genes.

The present invention also concerns polynucleotides encoding MAP2 or MAP2 homologs from *Ehrlichia canis* and *Ehrlichia chaffeensis*. MAP2 polynucleotide sequences of the invention can be used as vaccine compositions and in diagnostic assays. The polynucleotides can also be used to produce the MAP2 polypeptides encoded thereby.

Compositions comprising the subject polynucleotides can include appropriate nucleic acid vaccine vectors (plasmids), which are commercially available (*e.g.*, Vical, San Diego, CA). In addition, the compositions can include a pharmaceutically acceptable carrier, *e.g.*, saline. The pharmaceutically acceptable carriers are well known in the art and also are commercially available. For example, such acceptable carriers are described in E.W. Martin's *Remington's Pharmaceutical Science*, Mack Publishing Company, Easton, PA.

The subject invention also concerns polypeptides encoded by the subject polynucleotides. Specifically exemplified are the polypeptides encoded by the MAP-1 and VSA genes of *C. rumimontium, E. chaffeensis, E. canis* and the MP4 gene of *Anaplasma marginale*. Polypeptides uncoded by *E. chaffeensis* and *E. canis* MAP2 genes are also exemplified herein.

Also encompassed within the scope of the present invention are fragments and variants of the exemplified polynucleotides. Variants include polynucleotides and/or polypeptides having base or amino acid additions, deletions and substitutions in the sequence of the subject molecule so long as those variants have substantially the same activity or serologic reactivity as the native molecules. Also included are allelic variants of the subject polynucleotides. The polypeptides and peptides of the present invention can be used to raise antibodies that are reactive with the polypeptides disclosed herein. The polypeptides and peptides can also be used as molecular weight markers.

Another aspect of the subject invention concerns antibodies reactive with MAP-1 and MAP2 polypeptides disclosed herein. Antibodies can be monoclonal or polyclonal and can be produced using standard techniques known in the art. Antibodies of the invention can be used in diagnostic and therapeutic applications.

In a specific embodiment, the subject invention concerns a DNA vaccine (*e.g.*, VCL1010/MAP1) containing the major antigenic protein 1 gene (MAP1) driven by the human cytomegalovirus (HCMV) enhancer-promoter injected intramuscularly into 8-10 week-old female DBA/2 mice after treating them with 50 µl/muscle of 0.5% bupivacaine 3 days previously. Up to 75% of the VCL1010/MAP1-immunized mice seroconverted and reacted with MAP1 in antigen blots. Splenocytes from immunized mice, but not from control mice immunized with VCL1010 DNA (plasmid vector, Vical, San Diego) proliferated in response to recombinant MAP1 and *C. ruminantium* antigens in *in vitro* lymphocyte proliferation tests. These proliferating cells from mice immunized with VCL1010/MAP1 DNA secreted IFN-gamma and IL-2 at concentrations ranging from 610 pg/ml and 152 pg/ml to 1290 pg/ml and 310 pg/ml, respectively. In experiments testing different VCL1010/MAP1 DNA vaccine dose regimens (25-100 µg/dose, 2 or 4 immunizations), survival rates of 23% to 88% (35/92 survivors/total in all VCL1010/MAP1 immunized groups) were observed on challenge with 30LD50 of *C. ruminantium*. Survival rates of 0% to 3% (1/144 survivors/total in all control groups) were recorded for control mice immunized similarly with VCL1010 DNA or saline. Accordingly, the subject invention concerns the discovery that the gene encoding the MAP1 protein can induce protective immunity as a DNA vaccine against rickettsial disease.

The nucleic acid sequences described herein have other uses as well. For example, the nucleic acids of the subject invention can be useful as probes to identify complementary sequences within other nucleic acid molecules or genomes. Such use of probes can be applied to identify or distinguish infectious strains of organisms in diagnostic procedures or in rickettsial research where identification of particular organisms or strains is needed. As is well known in the art, probes can be made by labeling the nucleic acid sequences of interest according to accepted nucleic acid labeling procedures and techniques. A person of ordinary skill in the art would recognize that variations or fragments of the disclosed sequences which can specifically and selectively hybridize to the DNA of rickettsia can also function as a probe. It is within the ordinary skill of persons in the art, and does not require undue experimentation in view of the description provided herein, to determine whether a segment of the claimed DNA sequences is a fragment or variant which has characteristics of the full sequence, *e.g.*, whether it specifically and selectively hybridizes or can confer protection against rickettsial infection in accordance with the subject invention. In addition, with the benefit of the subject disclosure describing the specific sequences, it is within the ordinary skill of those persons in the art to label hybridizing sequences to produce a probe.

It is also well known in the art that restriction enzymes can be used to obtain functional fragments of the subject DNA sequences. For example, *Bal*31 exonuclease can be conveniently used for time-controlled limited digestion of DNA (commonly referred to as "erase-a-base" procedures). See, for example, Maniatis *et al.* (1982) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York; Wei *et al.* (1983) *J. Biol. Chem.* 258:13006-13512.

In addition, the nucleic acid sequences of the subject invention can be used as molecular weight markers in nucleic acid analysis procedures.

Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1

A nucleic acid vaccine construct was tested in animals for its ability to protect against death caused by infection with the rickettsia *Cowdria ruminantium*. The vaccine construct tested was the MAP1 gene of *C. ruminantium* inserted into plasmid VCL1010 (Vical, San Diego) under control of the human cytomegalovirus promoter-enhancer and intron A. In this study, seven groups containing 10 mice each were injected twice at 2-week intervals with either 100, 75, 50,

or 25 μg VCL1010/MAP1 DNA (V/M in Table 1 below), or 100, 50 μg VCL1010 DNA (V in Table 1) or saline (Sal.), respectively. Two weeks after the last injections, 8 mice/group were challenged with 30LD50 of *C. ruminantium* and clinical symptoms and survival monitored. The remaining 2 mice/group were not challenged and were used for lymphocyte proliferation tests and cytokine measurements. The results of the study are summarized in Table 1, below:

Table 1

	100 μg V/M	75 μg V/M	50 μg V/M	25 μg V/M	100 μg V	50 μg V	Sal.
Survived	5	7	5	3	0	0	0
Died	3	1	3	5	8	8	8

The VCL1010/MAP1 nucleic acid vaccine increased survival on challenge in all groups, with a total of 20/30 mice surviving compared to 0/24 in the control groups.

This study was repeated with another 6 groups, each containing 33 mice (a total of 198 mice). Three groups received 75 μg VCL1010/MAP1 DNA or VCL1010 DNA or saline (4 injections in all cases). Two weeks after the last injection, 30 mice/group were challenged with 30LD50 of *C. ruminantium* and 3 mice/group were sacrificed for lymphocyte proliferation tests and cytokine measurements. The results of this study are summarized in Table 2, below:

Table 2

	V/M 2 inj.	V 2 inj.	Sal. 2 inj.	V/M 4 inj.	V 4 inj.	Sal. 4 inj.
Survived	7	0	0	8	0	1
Died*	23	30	30	22	30	29

*In mice that died in both V/M groups, there was an increase in mean survival time of approximately 4 days compared to the controls ($p<0.05$).

Again, as summarized in Table 2, the VCL1010/MAP1 DNA vaccine increased the numbers of mice surviving in both immunized groups, although there was no apparent benefit of 2 additional injections. In these two experiments, there were a cumulative total of 35/92 (38%) surviving mice in groups receiving the VCL1010/MAP1 DNA vaccine compared to 1/144 (0.7%) surviving mice in the control groups. In both immunization and challenge trials

described above, splenocytes from VCL1010/MAP1 immunized mice, but not from control mice, specifically proliferated to recombinant MAP1 protein and to *C. ruminantium* in lymphocyte proliferation tests. These proliferating splenocytes secreted IL-2 and gamma-interferon at concentrations up to 310 and 1290 pg/ml respectively. These data show that protection against rickettsial infections can be achieved with a DNA vaccine. In addition, these experiments show MAP1-related proteins as vaccine targets.

Example 2

The MAP1 protein of *C. ruminantium* has significant similarity to MSP4 of *A. marginale*, and related molecules may also be presenting other rickettsial pathogens. To prove this, we used primers based on regions conserved between *C. ruminantium* and *A. marginale* in PCR to clone a MAP1-like gene from *E. chaffeensis*. The amino acid sequence derived from the cloned *E. chaffeensis* MAP1-like gene, and alignment with the corresponding genes of *C. ruminantium* and *A. marginale* is shown in Figure 1. We have now identified the regions of MAP1-like genes which are highly conserved between *Ehrlichia*, *Cowdria*, and *Anaplasma* and which can allow cloning of the analogous genes from other rickettsiae.

Example 3 – Cloning and sequence analysis of MAP1 homologue genes of *E. chaffeensis* and *E. canis*

Genes homologous to the major surface protein of *C. ruminantium* MAP1 were cloned from *E. chaffeensis* and *E. canis* by using PCR cloning strategies. The cloned segments represent a 4.6 kb genomic locus of *E. chaffeensis* and a 1.6 kb locus of *E. canis*. DNA sequence generated from these clones was assembled and is presented along with the deduced amino acid sequence in Figures 2A-2B (SEQ ID NOs. 7-11 and 14-18) and Figure 2C (SEQ ID NOs. 12-13 and 19-20). Significant features of the DNA include five very similar but nonidentical open reading frames (ORFs) for *E. chaffeensis* and two very similar, nonidentical ORFs for the *E. canis* cloned locus. The ORFs for both *Ehrlichia* spp. are separated by noncoding sequences ranging from 264 to 310 base pairs. The noncoding sequences have a higher A+T content (71.6% for *E. chaffeensis* and 76.1% for *E. canis*) than do the coding sequences (63.5% for *E. chaffeensis* and 68.0% for *E. canis*). A G-rich region -200 bases upstream from the initiation codon, sigma-70-like promoter sequences, putative ribosome binding sites (RBS), termination codons, and palindromic sequences near the termination codons are found in each of the *E. chaffeensis* noncoding sequences. The *E. canis* noncoding sequence has the same feature except for the G-rich region (Figure 2C; SEQ ID NOs. 12-13 and 19-20).

Sequence comparisons of the ORFs at the nucleotide and translated amino acid levels revealed a high degree of similarity between them. The similarity spanned the entire coding sequences, except in three regions where notable sequence variations were observed including some deletions/insertions (Variable Regions I, II and III). Despite the similarities, no two ORFs are identical. The cloned ORF 2, 3 and 4 of *E. chaffeensis* have complete coding sequences. The ORF1 is a partial gene having only 143 amino acids at the C-terminus whereas the ORF5 is nearly complete but lacks 5-7 amino acids and a termination codon. The cloned ORF2 of *E. canis* also is a partial gene lacking a part of the C-terminal sequence. The overall similarity between different ORFs at the amino acid level is 56.0% to 85.4% for *E. chaffeensis*, whereas for *E. canis* it is 53.3%. The similarity of *E. chaffeensis* ORFs to the MAP1 coding sequences reported for *C. ruminantium* isolates ranged from 55.5% to 66.7%, while for *E. canis* to *C. ruminantium* it is 48.5% to 54.2%. Due to their high degree of similarity to MAP1 surface antigen genes of *C. ruminantium* and since they are nonidentical to each other, the *E. chaffeensis* and *E. canis* ORFs are referred to herein as putative Variable Surface Antigen (VSA) genes. The apparent molecular masses of the predicted mature proteins of *E. chaffeensis* were 28.75 kDa for VSA2, 27.78 for VSA3, and 27.95 for VSA4, while *E. canis* VSA1 was slightly higher at 29.03 kDa. The first 25 amino acids in each VSA coding sequence were eliminated when calculating the protein size since they markedly resembled the signal sequence of *C. ruminantium* MAP1 and presumably would be absent from the mature protein. Predicted protein sizes for *E. chaffeensis* VSA1 and VSA5, and *E. canis* VSA2 were not calculated since the complete genes were not cloned.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
Applicant Name(s): University of Florida
Street Address: 223 Grinter Hall
City: Gainesville
State/Province: Florida
Country: US
Postal Code/Zip: 32611
Phone number: (352) 392-8929 Fax: (352) 392-6600

(ii) TITLE OF INVENTION: Nucleic Acid Vaccines Against Rickettsial Diseases and Methods of Use

(iii) NUMBER OF SEQUENCES: 24

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Saliwanchik, Lloyd & Saliwanchik
(B) STREET: 2421 N.W. 41st Street, Suite A-1
(C) CITY: Gainesville
(D) STATE: FL
(E) COUNTRY: USA
(F) ZIP: 32606

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: PCT
(B) FILING DATE: 17 October 1997
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Pace, Doran R.
(B) REGISTRATION NUMBER: 38,261
(C) REFERENCE/DOCKET NUMBER: UF-167C1

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 352-375-8100
(B) TELEFAX: 352-372-5800

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 864 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..861

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
ATG AAT TGC AAG AAA ATT TTT ATC ACA AGT ACA CTA ATA TCA TTA GTG        48
Met Asn Cys Lys Lys Ile Phe Ile Thr Ser Thr Leu Ile Ser Leu Val
  1               5                  10                  15

TCA TTT TTA CCT GGT GTG TCC TTT TCT GAT GTA ATA CAG GAA GAC AGC        96
Ser Phe Leu Pro Gly Val Ser Phe Ser Asp Val Ile Gln Glu Asp Ser
             20                  25                  30

AAC CCA GCA GGC AGT GTT TAC ATT AGC GCA AAA TAC ATG CCA ACT GCA       144
Asn Pro Ala Gly Ser Val Tyr Ile Ser Ala Lys Tyr Met Pro Thr Ala
         35                  40                  45

TCA CAT TTT GGT AAA ATG TCA ATC AAA GAA GAT TCA AAA AAT ACT CAA       192
Ser His Phe Gly Lys Met Ser Ile Lys Glu Asp Ser Lys Asn Thr Gln
     50                  55                  60

ACG GTA TTT GGT CTA AAA AAA GAT TGG GAT GGC GTT AAA ACA CCA TCA       240
Thr Val Phe Gly Leu Lys Lys Asp Trp Asp Gly Val Lys Thr Pro Ser
 65                  70                  75                  80

GAT TCT AGC AAT ACT AAT TCT ACA ATT TTT ACT GAA AAA GAC TAT TCT       288
Asp Ser Ser Asn Thr Asn Ser Thr Ile Phe Thr Glu Lys Asp Tyr Ser
                 85                  90                  95

TTC AGA TAT GAA AAC AAT CCG TTT TTA GGT TTC GCT GGA GCA ATT GGG       336
Phe Arg Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala Ile Gly
            100                 105                 110

TAC TCA ATG AAT GGA CCA AGA ATA GAG TTC GAA GTA TCC TAT GAA ACT       384
Tyr Ser Met Asn Gly Pro Arg Ile Glu Phe Glu Val Ser Tyr Glu Thr
        115                 120                 125

TTT GAT GTA AAA AAC CTA GGT GGC AAC TAT AAA AAC AAC GCA CAC ATG       432
Phe Asp Val Lys Asn Leu Gly Gly Asn Tyr Lys Asn Asn Ala His Met
    130                 135                 140

TAC TGT GCT TTA GAT ACA GCA GCA CAA AAT AGC ACT AAT GGC GCA GGA       480
Tyr Cys Ala Leu Asp Thr Ala Ala Gln Asn Ser Thr Asn Gly Ala Gly
145                 150                 155                 160

TTA ACT ACA TCT GTT ATG GTA AAA AAC GAA AAT TTA ACA AAT ATA TCA       528
Leu Thr Thr Ser Val Met Val Lys Asn Glu Asn Leu Thr Asn Ile Ser
                165                 170                 175

TTA ATG TTA AAT GCG TGT TAT GAT ATC ATG CTT GAT GGA ATA CCA GTT       576
Leu Met Leu Asn Ala Cys Tyr Asp Ile Met Leu Asp Gly Ile Pro Val
            180                 185                 190
```

```
TCT CCA TAT GTA TGT GCA GGT ATT GGC ACT GAC TTA GTG TCA GTA ATT       624
Ser Pro Tyr Val Cys Ala Gly Ile Gly Thr Asp Leu Val Ser Val Ile
        195                 200                 205

AAT GCT ACA AAT CCT AAA TTA TCT TAT CAA GGA AAG CTA GGC ATA AGT       672
Asn Ala Thr Asn Pro Lys Leu Ser Tyr Gln Gly Lys Leu Gly Ile Ser
    210                 215                 220

TAC TCA ATC AAT TCT GAA GCT TCT ATC TTT ATC GGT GGA CAT TTC CAT       720
Tyr Ser Ile Asn Ser Glu Ala Ser Ile Phe Ile Gly Gly His Phe His
225                 230                 235                 240

AGA GTT ATA GGT AAT GAA TTT AAA GAT ATT GCT ACC TTA AAA ATA TTT       768
Arg Val Ile Gly Asn Glu Phe Lys Asp Ile Ala Thr Leu Lys Ile Phe
                245                 250                 255

ACT TCA AAA ACA GGA ATA TCT AAT CCT GGC TTT GCA TCA GCA ACA CTT       816
Thr Ser Lys Thr Gly Ile Ser Asn Pro Gly Phe Ala Ser Ala Thr Leu
            260                 265                 270

GAT GTT TGT CAC TTT GGT ATA GAA ATT GGA GGA AGG TTT GTA TTT           861
Asp Val Cys His Phe Gly Ile Glu Ile Gly Gly Arg Phe Val Phe
        275                 280                 285

TAA                                                                  864
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 287 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Asn Cys Lys Lys Ile Phe Ile Thr Ser Thr Leu Ile Ser Leu Val
  1               5                  10                  15

Ser Phe Leu Pro Gly Val Ser Phe Ser Asp Val Ile Gln Glu Asp Ser
             20                  25                  30

Asn Pro Ala Gly Ser Val Tyr Ile Ser Ala Lys Tyr Met Pro Thr Ala
         35                  40                  45

Ser His Phe Gly Lys Met Ser Ile Lys Glu Asp Ser Lys Asn Thr Gln
     50                  55                  60

Thr Val Phe Gly Leu Lys Lys Asp Trp Asp Gly Val Lys Thr Pro Ser
 65                  70                  75                  80

Asp Ser Ser Asn Thr Asn Ser Thr Ile Phe Thr Glu Lys Asp Tyr Ser
                 85                  90                  95
```

```
Phe Arg Tyr Glu Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala Ile Gly
            100                 105                 110

Tyr Ser Met Asn Gly Pro Arg Ile Glu Phe Glu Val Ser Tyr Glu Thr
        115                 120                 125

Phe Asp Val Lys Asn Leu Gly Gly Asn Tyr Lys Asn Asn Ala His Met
    130                 135                 140

Tyr Cys Ala Leu Asp Thr Ala Ala Gln Asn Ser Thr Asn Gly Ala Gly
145                 150                 155                 160

Leu Thr Thr Ser Val Met Val Lys Asn Glu Asn Leu Thr Asn Ile Ser
                165                 170                 175

Leu Met Leu Asn Ala Cys Tyr Asp Ile Met Leu Asp Gly Ile Pro Val
            180                 185                 190

Ser Pro Tyr Val Cys Ala Gly Ile Gly Thr Asp Leu Val Ser Val Ile
        195                 200                 205

Asn Ala Thr Asn Pro Lys Leu Ser Tyr Gln Gly Lys Leu Gly Ile Ser
    210                 215                 220

Tyr Ser Ile Asn Ser Glu Ala Ser Ile Phe Ile Gly Gly His Phe His
225                 230                 235                 240

Arg Val Ile Gly Asn Glu Phe Lys Asp Ile Ala Thr Leu Lys Ile Phe
                245                 250                 255

Thr Ser Lys Thr Gly Ile Ser Asn Pro Gly Phe Ala Ser Ala Thr Leu
            260                 265                 270

Asp Val Cys His Phe Gly Ile Glu Ile Gly Gly Arg Phe Val Phe
        275                 280                 285
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 842 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..840

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
ATG AAT TAC AAA AAA AGT TTC ATA ACA GCG ATT GAT ATC ATT AAT ATC        48
Met Asn Tyr Lys Lys Ser Phe Ile Thr Ala Ile Asp Ile Ile Asn Ile
        290                 295                 300

CTT CTC TTA CCT GGA GTA TCA TTT TCC GAC CCA AGG CAG GTA GTG GTC        96
Leu Leu Leu Pro Gly Val Ser Phe Ser Asp Pro Arg Gln Val Val Val
    305                 310                 315

ATT AAC GGT AAT TTC TAC ATC AGT GGA AAA TAC GAT GCC AAG GCT TCG       144
Ile Asn Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Asp Ala Lys Ala Ser
320                 325                 330                 335

CAT TTT GGA GTA TTC TCT GCT AAG GAA GAA AGA AAT ACA ACA GTT GGA       192
His Phe Gly Val Phe Ser Ala Lys Glu Glu Arg Asn Thr Thr Val Gly
                340                 345                 350

GTG TTT GGA CTG AAG CAA AAT TGG GAC GGA AGC GCA ATA TCC AAC TCC       240
Val Phe Gly Leu Lys Gln Asn Trp Asp Gly Ser Ala Ile Ser Asn Ser
            355                 360                 365

TCC CCA AAC GAT GTA TTC ACT GTC TCA AAT TAT TCA TTT AAA TAT GAA       288
Ser Pro Asn Asp Val Phe Thr Val Ser Asn Tyr Ser Phe Lys Tyr Glu
        370                 375                 380

AAC AAC CCG TTT TTA GGT TTT GCA GGA GCT ATT GGT TAC TCA ATG GAT       336
Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala Ile Gly Tyr Ser Met Asp
    385                 390                 395

GGT CCA AGA ATA GAG CTT GAA GTA TCT TAT GAA ACA TTT GAT GTA AAA       384
Gly Pro Arg Ile Glu Leu Glu Val Ser Tyr Glu Thr Phe Asp Val Lys
400                 405                 410                 415

AAT CAA GGT AAC AAT TAT AAG AAT GAA GCA CAT AGA TAT TGT GCT CTA       432
Asn Gln Gly Asn Asn Tyr Lys Asn Glu Ala His Arg Tyr Cys Ala Leu
                420                 425                 430

TCC CAT AAC TCA GCA GCA GAC ATG AGT AGT GCA AGT AAT AAT TTT GTC       480
Ser His Asn Ser Ala Ala Asp Met Ser Ser Ala Ser Asn Asn Phe Val
            435                 440                 445

TTT CTA AAA AAT GAA GGA TTA CTT GAC ATA TCA TTT ATG CTG AAC GCA       528
Phe Leu Lys Asn Glu Gly Leu Leu Asp Ile Ser Phe Met Leu Asn Ala
        450                 455                 460

TGC TAT GAC GTA GTA GGC GAA GGC ATA CCT TTT TCT CCT TAT ATA TGC       576
Cys Tyr Asp Val Val Gly Glu Gly Ile Pro Phe Ser Pro Tyr Ile Cys
    465                 470                 475

GCA GGT ATC GGT ACT GAT TTA GTA TCC ATG TTT GAA GCT ACA AAT CCT       624
Ala Gly Ile Gly Thr Asp Leu Val Ser Met Phe Glu Ala Thr Asn Pro
480                 485                 490                 495

AAA ATT TCT TAC CAA GGA AAG TTA GGT TTA AGC TAC TCT ATA AGC CCA       672
Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Ser Tyr Ser Ile Ser Pro
                500                 505                 510
```

```
GAA GCT TCT GTG TTT ATT GGT GGG CAC TTT CAT AAG GTA ATA GGG AAC       720
Glu Ala Ser Val Phe Ile Gly Gly His Phe His Lys Val Ile Gly Asn
            515                 520                 525

GAA TTT AGA GAT ATT CCT ACT ATA ATA CCT ACT GGA TCA ACA CTT GCA       768
Glu Phe Arg Asp Ile Pro Thr Ile Ile Pro Thr Gly Ser Thr Leu Ala
        530                 535                 540

GGA AAA GGA AAC TAC CCT GCA ATA GTA ATA CTG GAT GTA TGC CAC TTT       816
Gly Lys Gly Asn Tyr Pro Ala Ile Val Ile Leu Asp Val Cys His Phe
    545                 550                 555

GGA ATA GAA ATG GGA GGA AGG TTT AA                                    842
Gly Ile Glu Met Gly Gly Arg Phe
560                 565
```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 280 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Met Asn Tyr Lys Lys Ser Phe Ile Thr Ala Ile Asp Ile Ile Asn Ile
  1               5                  10                  15

Leu Leu Leu Pro Gly Val Ser Phe Ser Asp Pro Arg Gln Val Val Val
             20                  25                  30

Ile Asn Gly Asn Phe Tyr Ile Ser Gly Lys Tyr Asp Ala Lys Ala Ser
         35                  40                  45

His Phe Gly Val Phe Ser Ala Lys Glu Glu Arg Asn Thr Thr Val Gly
     50                  55                  60

Val Phe Gly Leu Lys Gln Asn Trp Asp Gly Ser Ala Ile Ser Asn Ser
 65                  70                  75                  80

Ser Pro Asn Asp Val Phe Thr Val Ser Asn Tyr Ser Phe Lys Tyr Glu
                 85                  90                  95

Asn Asn Pro Phe Leu Gly Phe Ala Gly Ala Ile Gly Tyr Ser Met Asp
            100                 105                 110

Gly Pro Arg Ile Glu Leu Glu Val Ser Tyr Glu Thr Phe Asp Val Lys
        115                 120                 125

Asn Gln Gly Asn Asn Tyr Lys Asn Glu Ala His Arg Tyr Cys Ala Leu
    130                 135                 140
```

```
Ser His Asn Ser Ala Ala Asp Met Ser Ser Ala Ser Asn Asn Phe Val
145                 150                 155                 160

Phe Leu Lys Asn Glu Gly Leu Leu Asp Ile Ser Phe Met Leu Asn Ala
                165                 170                 175

Cys Tyr Asp Val Val Gly Glu Gly Ile Pro Phe Ser Pro Tyr Ile Cys
            180                 185                 190

Ala Gly Ile Gly Thr Asp Leu Val Ser Met Phe Glu Ala Thr Asn Pro
        195                 200                 205

Lys Ile Ser Tyr Gln Gly Lys Leu Gly Leu Ser Tyr Ser Ile Ser Pro
    210                 215                 220

Glu Ala Ser Val Phe Ile Gly Gly His Phe His Lys Val Ile Gly Asn
225                 230                 235                 240

Glu Phe Arg Asp Ile Pro Thr Ile Ile Pro Thr Gly Ser Thr Leu Ala
                245                 250                 255

Gly Lys Gly Asn Tyr Pro Ala Ile Val Ile Leu Asp Val Cys His Phe
            260                 265                 270

Gly Ile Glu Met Gly Gly Arg Phe
        275                 280
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 849 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..846

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
ATG AAT TAC AGA GAA TTG TTT ACA GGG GGC CTG TCA GCA GCC ACA GTC        48
Met Asn Tyr Arg Glu Leu Phe Thr Gly Gly Leu Ser Ala Ala Thr Val
                285                 290                 295

TGC GCC TGC TCC CTA CTT GTT AGT GGG GCC GTA GTG GCA TCT CCC ATG        96
Cys Ala Cys Ser Leu Leu Val Ser Gly Ala Val Val Ala Ser Pro Met
            300                 305                 310

AGT CAC GAA GTG GCT TCT GAA GGG GGA GTA ATG GGA GGT AGC TTT TAC       144
Ser His Glu Val Ala Ser Glu Gly Gly Val Met Gly Gly Ser Phe Tyr
        315                 320                 325
```

```
GTG GGT GCG GCC TAC AGC CCA GCA TTT CCT TCT GTT ACC TCG TTC GAC        192
Val Gly Ala Ala Tyr Ser Pro Ala Phe Pro Ser Val Thr Ser Phe Asp
    330                 335                 340

ATG CGT GAG TCA AGC AAA GAG ACC TCA TAC GTT AGA GGC TAT GAC AAG        240
Met Arg Glu Ser Ser Lys Glu Thr Ser Tyr Val Arg Gly Tyr Asp Lys
345                 350                 355                 360

AGC ATT GCA ACG ATT GAT GTG AGT GTG CCA GCA AAC TTT TCC AAA TCT        288
Ser Ile Ala Thr Ile Asp Val Ser Val Pro Ala Asn Phe Ser Lys Ser
                365                 370                 375

GGC TAC ACT TTT GCC TTC TCT AAA AAC TTA ATC ACG TCT TTC GAC GGC        336
Gly Tyr Thr Phe Ala Phe Ser Lys Asn Leu Ile Thr Ser Phe Asp Gly
            380                 385                 390

GCT GTG GGA TAT TCT CTG GGA GGA GCC AGA GTG GAA TTG GAA GCG AGC        384
Ala Val Gly Tyr Ser Leu Gly Gly Ala Arg Val Glu Leu Glu Ala Ser
        395                 400                 405

TAC AGA AGG TTT GCT ACT TTG GCG GAC GGG CAG TAC GCA AAA AGT GGT        432
Tyr Arg Arg Phe Ala Thr Leu Ala Asp Gly Gln Tyr Ala Lys Ser Gly
    410                 415                 420

GCG GAA TCT CTG GCA GCT ATT ACC CGC GAC GCT AAC ATT ACT GAG ACC        480
Ala Glu Ser Leu Ala Ala Ile Thr Arg Asp Ala Asn Ile Thr Glu Thr
425                 430                 435                 440

AAT TAC TTC GTA GTC AAA ATT GAT GAA ATC ACA AAC ACC TCA GTC ATG        528
Asn Tyr Phe Val Val Lys Ile Asp Glu Ile Thr Asn Thr Ser Val Met
                445                 450                 455

TTA AAT GGC TGC TAT GAC GTG CTG CAC ACA GAT TTA CCT GTG TCC CCG        576
Leu Asn Gly Cys Tyr Asp Val Leu His Thr Asp Leu Pro Val Ser Pro
            460                 465                 470

TAT GTA TGT GCC GGG ATA GGC GCA AGC TTT GTT GAC ATC TCT AAG CAA        624
Tyr Val Cys Ala Gly Ile Gly Ala Ser Phe Val Asp Ile Ser Lys Gln
        475                 480                 485

GTA ACC ACA AAG CTG GCC TAC AGG GGC AAG GTT GGG ATT AGC TAC CAG        672
Val Thr Thr Lys Leu Ala Tyr Arg Gly Lys Val Gly Ile Ser Tyr Gln
    490                 495                 500

TTT ACT CCG GAA ATA TCC TTG GTG GCA GGT GGG TTC TAC CAC GGG CTA        720
Phe Thr Pro Glu Ile Ser Leu Val Ala Gly Gly Phe Tyr His Gly Leu
505                 510                 515                 520

TTT GAT GAG TCT TAC AAG GAC ATT CCC GCA CAC AAC AGT GTA AAG TTC        768
Phe Asp Glu Ser Tyr Lys Asp Ile Pro Ala His Asn Ser Val Lys Phe
                525                 530                 535

TCT GGA GAA GCA AAA GCC TCA GTC AAA GCG CAT ATT GCT GAC TAC GGC        816
Ser Gly Glu Ala Lys Ala Ser Val Lys Ala His Ile Ala Asp Tyr Gly
            540                 545                 550
```

```
TTT AAC CTT GGA GCA AGA TTC CTG TTC AGC TAA                          849
Phe Asn Leu Gly Ala Arg Phe Leu Phe Ser
        555                 560
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 282 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met Asn Tyr Arg Glu Leu Phe Thr Gly Gly Leu Ser Ala Ala Thr Val
  1               5                  10                  15

Cys Ala Cys Ser Leu Leu Val Ser Gly Ala Val Val Ala Ser Pro Met
             20                  25                  30

Ser His Glu Val Ala Ser Glu Gly Gly Val Met Gly Gly Ser Phe Tyr
         35                  40                  45

Val Gly Ala Ala Tyr Ser Pro Ala Phe Pro Ser Val Thr Ser Phe Asp
     50                  55                  60

Met Arg Glu Ser Ser Lys Glu Thr Ser Tyr Val Arg Gly Tyr Asp Lys
 65                  70                  75                  80

Ser Ile Ala Thr Ile Asp Val Ser Val Pro Ala Asn Phe Ser Lys Ser
                 85                  90                  95

Gly Tyr Thr Phe Ala Phe Ser Lys Asn Leu Ile Thr Ser Phe Asp Gly
            100                 105                 110

Ala Val Gly Tyr Ser Leu Gly Gly Ala Arg Val Glu Leu Glu Ala Ser
        115                 120                 125

Tyr Arg Arg Phe Ala Thr Leu Ala Asp Gly Gln Tyr Ala Lys Ser Gly
    130                 135                 140

Ala Glu Ser Leu Ala Ala Ile Thr Arg Asp Ala Asn Ile Thr Glu Thr
145                 150                 155                 160

Asn Tyr Phe Val Val Lys Ile Asp Glu Ile Thr Asn Thr Ser Val Met
                165                 170                 175

Leu Asn Gly Cys Tyr Asp Val Leu His Thr Asp Leu Pro Val Ser Pro
            180                 185                 190

Tyr Val Cys Ala Gly Ile Gly Ala Ser Phe Val Asp Ile Ser Lys Gln
        195                 200                 205
```

```
Val Thr Thr Lys Leu Ala Tyr Arg Gly Lys Val Gly Ile Ser Tyr Gln
    210                 215                 220

Phe Thr Pro Glu Ile Ser Leu Val Ala Gly Gly Phe Tyr His Gly Leu
225                 230                 235                 240

Phe Asp Glu Ser Tyr Lys Asp Ile Pro Ala His Asn Ser Val Lys Phe
                245                 250                 255

Ser Gly Glu Ala Lys Ala Ser Val Lys Ala His Ile Ala Asp Tyr Gly
            260                 265                 270

Phe Asn Leu Gly Ala Arg Phe Leu Phe Ser
        275                 280
```

Claims

1. A composition comprising a polynucleotide which encodes a polypeptide having the characteristic of eliciting an immune response protective against disease or death caused by a rickettsial pathogen.

2. The composition, according to claim 1, wherein said rickettsial pathogen is selected from the group consisting of *Rickettsia* spp., *Ehrlichia* spp., *Anaplasma* spp., and *Cowdria* spp.

3. The composition, according to claim 1, wherein said polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NOS. 16-20, SEQ ID NO. 23, and SEQ ID NO. 24, or a fragment thereof.

4. The composition, according to claim 1, wherein said polynucleotide has a nucleic acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NOS. 9-13, SEQ ID NO. 21, and SEQ ID NO. 22, or a fragment thereof.

5. The composition, according to claim 4, wherein said polynucleotide has a nucleic acid sequence of SEQ ID NO. 3, or a fragment thereof.

6. The composition, according to claim 1, wherein said polynucleotide further comprises a nucleic acid vaccine vector.

7. The composition, according to claim 1, further comprising a pharmaceutically acceptable carrier.

8. A polynucleotide encoding a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO. 4, SEQ ID NOS. 14-20, SEQ ID NOS. 23-24, and fragments thereof.

9. The polynucleotide, according to claim 8, said polynucleotide having a nucleic acid sequence selected from the group consisting of SEQ ID NO. 3, SEQ ID NOS. 7-13, and SEQ ID NOS. 21-22.

10. A method for protecting a susceptible animal host against disease or death caused by a rickettsial pathogen, said method comprising administering an effective amount of a polynucleotide encoding polypeptide having the characteristic of eliciting an immune response protective against said rickettsial pathogen.

11. The method, according to claim 10, wherein said rickettsial pathogen is selected from the group consisting of *Rickettsia* spp., *Ehrlichia* spp., *Anaplasma* spp., and *Cowdria* spp.

12. The method, according to claim 10, wherein said polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NOS. 16-20, SEQ ID NO. 23, and SEQ ID NO. 24, or a fragment thereof.

13. The method, according to claim 10, wherein said polynucleotide has a nucleic acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NOS. 9-13, SEQ ID NO. 21, and SEQ ID NO. 22.

14. The method, according to claim 13, wherein said polynucleotide has the nucleic acid sequence of SEQ ID NO. 1.

15. The method, according to claim 13, wherein said polynucleotide has the nucleic acid sequence of SEQ ID NO. 3.

16. The method, according to claim 13, wherein said polynucleotide has the nucleic acid sequence of SEQ ID NO. 5.

17. The method, according to claim 10, wherein said nucleic acid further comprises an appropriate nucleic acid vector.

18. The method, according to claim 10, wherein said composition further comprises a pharmaceutically acceptable carrier.

19. A method for detecting, in a human or animal, antibodies associated with infection by *Ehrlichia*, wherein said method comprises contacting a biological fluid from said human or animal with a polypeptide selected from the group consisting of SEQ ID NO. 4, SEQ ID NOS. 14-20, SEQ ID NOS. 23-24, and fragments thereof.

FIG. 1A


C.r. ATGAATTGCAAGAAAATTTTTA----------TCACAAGTACACTAATATCATTAGTG
E.c. ATGAATTACAAAAAAAGTTTCA----------TAACAGCG-ATTGATATCATTAATA
A.m. ATGAATTACAGAGAATTGTTTACAGGGGGCCTG-TCAGCAGCC-ACAGTCTGCGCCTGCT
C.r. TCATTTT--TACCTGGTGTGTCCTTTTCTGATGTAATACAGGAAGACAGCAACCCAGCAG
E.c. TCCTTCTCTTACCTGGAGTATCATTTTCCGACCCAAGGCAGGTAGTGGTCA---TTAACG
A.m. CCCTACTTGTTAGTGGGGCCGTAGTGGCATCTCCCATGAGTCACGAAGTGGCTTCTGAAG
C.r. GCAGTGTTTACATTAGCGCAAAATACATGCCAACTGCATCACATTTTGGTAAAATGTCAA
E.c. GTAATTTCTACATCAGTGGAAAATACGATGCCAAGGCTTCGCATTTTGGAGTATTCTCTG
A.m. GGGGAGTAATGGGAGGTAGCTTTTACGTGGGTGCGGCCT-ACAGCCCAGCATTTCCTTCT
C.r. TCAAAGAAGATTCAAAAAATACTCAAACGGTATTTGGTCTAAAAAAAGATTGGGATGGCG
E.c. CTAAGGAAGAAAGAAATACAACAGTTGGAGTGTTTGGACTGAAGCAAAATTGGGACGGAA
A.m. GTTACCTCGTTCGACATGCGTGAGTCAAGCAAAGAGACCTCA--TACGTTAGAGGCTATG
C.r. TTAAAACACCATCAGATTCTAGCAATACTAATTCTACAATTTTTACTGAAAAAGACTATT
E.c. GCGCAATATC--CAACTCCTCCCCAAACGA-------TGTATTCACTGTCTCAAATTATT
A.m. ACAAGAGCATTGCAACGATTGATGTGAGTGTGCCAGCAAACTTTTCCAAATCTGGCTACA
C.r. CTTTCAGATATGAAAACAATCCGTTTTTAGGTTTCGCTGGAGCAATTGGGTACTCAATGA
E.c. CATTTAAATATGAAAACAACCCGTTTTTAGGTTTTGCAGGAGCTATTGGTTACTCAATGG
A.m. CTTTTGCCTTCTCTAAAAACTTAATCACGTCTTTCGACGGCGCTGTGGGATATTCTCTGG

FIG. 1B


C.r. ATGGACCAAGAATAGAGTTCGAAGTATCCTATGAAACTTTTGATGTAAAAAACCTAGGTG
E.c. ATGGTCCAAGAATAGAGCTTGAAGTATCTTATGAAACATTTGATGTAAAAAATCAAGGTA
A.m. GAGGAGCCAGAGTGGAATTGGAAGCGAGCTACAGAAGGTTTGCTACTTTGGCGGACGGGC
C.r. GCAACTATAAAAACAACGCACACATGTACTGTGCTTTAGATACAGCAGCACAAAATAGCA
E.c. ACAATTATAAGAATGAAGCACATAGATATTGTGCTCTATCCCATAACTCAGCAGCAGACA
A.m. AGTACGCAAAAAGTG----------GTGCGGAATCTCTGGCAGCTATTACCCGCG
C.r. CTAATGGCGCAGGATTAACTACATCTGTTATGGTAAAAAACGAAAATTTAACAAATATAT
E.c. TGAGTAGTGCAAG---TAATAATTTTGTCTTTCTAAAAAATGAAGGATTACTTGACATAT
A.m. ACGCTAACATTACTGAGACCAATTACTTCGTAGTCAAAATTGATGAAATCACAAACACCT
C.r. CATTAATGTTAAATGCGTGTTATGATATCATGCTTGATGGAATACCAGTTTCTCCATATG
E.c. CATTTATGCTGAACGCATGCTATGACGTAGTAGGCGAAGGCATACCTTTTTCTCCTTATA
A.m. CAGTCATGTTAAATGGCTGCTATGACGTGCTGCACACAGATTTACCTGTGTCCCCGTATG
C.r. TATGTGCAGGTATTGGCACTGACTTAGTGTCAGTAATTAATGCTACAAATCCTAAATTAT
E.c. TATGCGCAGGTATCGGTACTGATTTAGTATCCATGTTTGAAGCTACAAATCCTAAAATTT
A.m. TATGTGCCGGGATAGGCGCAAGCTTTGTTGACATCTCTAAGCAAGTAACCACAAAGCTGG
C.r. CTTATCAAGGAAAGCTAGGCATAAGTTACTCAATCAATTCTGAAGCTTCTATCTTTATCG
E.c. CTTACCAAGGAAAGTTAGGTTTAAGCTACTCTATAAGCCCAGAAGCTTCTGTGTTTATTG
A.m. CCTACAGGGGCAAGGTTGGGATTAGCTACCAGTTTACTCCGGAAATATCCTTGGTGGCAG

FIG. 1C


C.r. GTGGACATTTCCATAGAGTTATAGGTAATGAATTTAAAGATATTGCTACCTTAAAAATAT
E.c. GTGGGCACTTTCATAAGGTAATAGGGAACGAATTTAGAGATATTCCTACTATAATACCTA
A.m. GTGGGTTCTACCACGGGCTATTTGATGAGTCTTACAAGGACATTCCCGCACACAACAGTG
C.r. TTACTTCAAAAACAGGAATATCTAATCCTGGCTTTGCATCAGCAACACTTGATGTTTGTC
E.c. CTGGATCAACACTTGCAGGAAAAGGAAACTACCCTGCAATAGTAATACTGGATGTATGCC
A.m. TAAAGTTCTCTGGAGAAGCAAAA----------GCCTCAGTCAAAGCGCATATTGCTG
C.r. ACTTTGGTATAGAAATTGGAGGAAGGTTTGTATTTTAA---
E.c. ACTTTGGAATAGAAATGGGAGGAAGGTTTAA----------
A.m. ACTACGGCTTTAACCTTGGAGCAAGATTCCTGTTCAGCTAA



FIG. 2A



FIG. 2B

```
   1 tggtgtaaatatgaaatataaaaaaactttacagtaactgcattagtattattaacttc
      RBS      M  K  Y  K  K  T  F  T  V  T  A  L  V  L  L  T  S
  61 ctttacacattttatacctttttatagtccagcacgtgccagtacaattcacaacttcta
      F  T  H  F  I  P  F  Y  S  P  A  R  A  S  T  I  H  N  F  Y
 121 cattagtggaaaatatatgccaacagcgtcacattttggaatttttcagcttaaagaaga
      I  S  G  K  Y  M  P  T  A  S  H  F  G  I  F  S  A  K  E  E
 181 acaaagttttactaaggtattagttgggttagatcaacgattatcacataatattataaa
      Q  S  F  T  K  V  L  V  G  L  D  Q  R  L  S  H  N  I  I  N
 241 caataatgatacagcaaagagtctttaaggttcaaaattatttcatttaaatacaaaaataa
      N  N  D  T  A  K  S  L  K  V  Q  N  Y  S  F  K  Y  K  N  N
 301 cccatttctaggatttgcaggagctattggttattcaataggcaatttcaagaatagaact
      P  F  L  G  F  A  G  A  I  G  Y  S  I  G  N  S  R  I  E  L
 361 agaagtatcacatgaaatatttgatactaaaaacccaggaaacaattatttaaatgactc
      E  V  S  H  E  I  F  D  T  K  N  P  G  N  N  Y  L  N  D  S
 421 tcacaaatattgcgctttatctcatggaagtcacatatgcagtgatggaaatagcggaga
      H  K  Y  C  A  L  S  H  G  S  H  I  C  S  D  G  N  S  G  D
 481 ttggtacactgcaaaaactgataagtttgtacttctgaaaaatgaaggtttacttgacgt
      W  Y  T  A  K  T  D  K  F  V  L  L  K  N  E  G  L  L  D  V
 541 ctcatttatgttaaacgcatgttatgacataacaactgaaaaaatgccttttttcacttta
      S  F  M  L  N  A  C  Y  D  I  T  T  E  K  M  P  F  S  P  Y
 601 tatatgtgcaggtattggtactgatctcatatctatgtttgagacaacacaaaacaaaat
      I  C  A  G  I  G  T  D  L  I  S  M  F  E  T  T  Q  N  K  I
 661 atcttatcaaggaaagttaggtttaaactatactataaactcaagagtttctgtttttgc
      S  Y  Q  G  K  L  G  L  N  Y  T  I  N  S  R  V  S  V  F  A
 721 aggtgggcactttcataaggtaataggtaatgaatttaaaggtattcctactctattacc
      G  G  H  F  H  K  V  I  G  N  E  F  K  G  I  P  T  L  L  P
 781 tgatggattcaaacattaaagtacaacagtctgcaacagtaacattagatgtgtgccattt
      D  G  S  N  I  K  V  Q  Q  S  A  T  V  T  L  D  V  C  H  F
 841 cgggttagagattggaagtagatttttcttttaatacttctattgtacatgttaaaaata
      G  L  E  I  G  S  R  F  F  F  *
 901 gtactagtttgcttctgtggtttataaacgcaagagagaaatagttagtaataaattaga
 961 aagttaaatattagaaaagtcatatgtttttcattgtcattgatactcaactaaaagtag
1021 tataaatgttacttattaataatttacgtagtatattaaatttccttacaaaagccac
1081 tagtatttatactaaaagctatacttggcttgtatttaatttgtatttttactactgt
     -35                -10
1141 taatttacttcactgtttctggtgtaaatatgaattgtaaaaaagttttcacaataagt
                        RBS      M  N  C  K  K  V  F  T  I  S
1201 gcattgatatcatccatatacttcctacctaatgtctcatactctaacccagtatatggt
     A  L  I  S  S  I  Y  F  L  P  N  V  S  Y  S  N  P  V  Y  G
1261 aacagtatgtatggtaatttttacatatcaggaaagtacatgccaagtgtttcctatttt
     N  S  M  Y  G  N  F  Y  I  S  G  K  Y  M  P  S  V  P  H  F
1321 ggaatttttcagctgaagaagagaaaaaaaagacaactgtagtatatggcttaaaagaa
     G  I  F  S  A  E  E  E  K  K  K  T  T  V  V  Y  G  L  K  E
1381 aactgggcaggagatgcaatatctagtcaaagtccagatgataatttaccattcgaaat
     N  W  A  G  D  A  I  S  S  Q  S  P  D  D  N  F  T  I  R  N
1441 tactcattcaagtatgcaagcaacaagtttttagggtttgcagtagctattggttactcg
     Y  S  F  K  Y  A  S  N  K  F  L  G  F  A  V  A  I  G  Y  S
1501 ataggcagtccaagaatagaagttgagatgtcttatgaagcatttgatgtaaaaaatcaa
     I  G  S  P  R  I  E  V  E  M  S  Y  E  A  F  D  V  K  N  Q
1561 ggtaacaatt
     G  N  N
```

FIG. 2C

```
   1  acatgtatacattatagtaacaaatgttaccgtattttattcataagttaagtaaaatct

  61  ataccattctctttcactttatcagaagacttttatttatcacaaactcatgacgtatag

 121  tgtcacaaataaacacactgcaactgcaatcactacgtaaaactttaactcttcttttttc

 181  acaactaaaatactaataaaagtaatatagtataaaaaatcttaagtaacTTGACAtaat
                                                        -35
 241  attactctgataTAGCATatgtctagtatctctatactaaacgtttatataattGGAGca
                   -10
 301  tattaATGAAAGCTATCAAATTCATACTTAATGTCTGCTTACTATTTGCAGCAATATTTT
          M  K  A  I  K  F  I  L  N  V  C  L  L  F  A→ A  I  F  L

 361  TAGGGTATTCCTATATTACAAAACAAGGCATATTTCAAACAAAACATCATGATACACCTA
        G  Y  S  Y  I  T  K  Q  G  I  F  Q  T  K  H  H  D  T  P  N

 421  ATACTACTATACCAAATGAAGACGGTATTCAATCTAGCTTTAGCTTAATCAATCAAGACG
        T  T  I  P  N  E  D  G  I  Q  S  S  F  S  L  I  N  Q  D  G

 481  GTAAAACAGTAACCAGCCAAGATTTCCTAGGGAAACACATGTTAGTTTTGTTTGGATTCT
        K  T  V  T  S  Q  D  F  L  G  K  H  M  L  V  L  F  G  F  S

 541  CTGCATGTAAAAGCATTTGCCCTGCAGAATTGGGATTAGTATCTGAAGCACTTGCACAAC
        A  C  K  S  I  C  P  A  E  L  G  L  V  S  E  A  L  A  Q  L

 601  TTGGTAATAATGCAGACAAATTACAAGTAATTTTTATTACAATTGATCCAAAAAATGATA
        G  N  N  A  D  K  L  Q  V  I  F  I  T  I  D  P  K  N  D  T

 661  CTGTAGAAAAATTAAAAGAATTTCATGAACATTTTGATTCAAGAATTCAAATGTTAACAG
        V  E  K  L  K  E  F  H  E  H  F  D  S  R  I  Q  M  L  T  G

 721  GAAATACTGAAGACATTAATCAAATAATTAAAAATTATAAAATATATGTTGGACAAGCAG
        N  T  E  D  I  N  Q  I  I  K  N  Y  K  I  Y  V  G  Q  A  D

 781  ATAAAGATCATCAAATTAACCATTCTGCAATAATGTACCTTATTGACAAAAAAGGATCAT
        K  D  H  Q  I  N  H  S  A  I  M  Y  L  I  D  K  K  G  S  Y

 841  ATCTTTCACACTTCATTCCAGATTTAAAATCACAAGAAAATCAAGTAGATAAGTTACTAT
        L  S  H  F  I  P  D  L  K  S  Q  E  N  Q  V  D  K  L  L  S

 901  CTTTAGTTAAGCAGTATCTGTAAtttaataattaattAAAGagaatagtacacaCTTTtt
        L  V  K  Q  Y  L  *

 961  ataaattcatggaatacgttggatgagtaggttttttttagtatttttagtgctaataac
1021  attggcat
```

FIG. 3A

```
   1  ggaaatctcatgtaaacgtgaaatactatattctttttaaataccaatacaattgaata

  61  caaaaaaactttacaacttattatgtttatcttaaaaccttattttaagattccttatg

 121  tcacaaaataacaaaaatactatttacaaaatacaccacaatttcatcaaataaaaaaaa

 181  ctatacactttattatactacagtagatataccataaaagattttaagtaacTTGACAta
                                                          -35
 241  atattaccttggtaTAGCATatgattcagtattttatattaaaatttattatgtattGGA
                      -10
 301  GcataaaATGAAAGTTATCAAATTTATACTTAATATCTGTTTATTATTTGCAGCAATTTT
           M  K  V  I  K  F  I  L  N  I  C  L  L  F  A →A  I  F

 361  TCTAGGATATTCCTACGTAACAAAACAAGGCATTTTTCAAGTAAGAGATCATAACACTCC
       L  G  Y  S  Y  V  T  K  Q  G  I  F  Q  V  R  D  H  N  T  P

 421  CAATACAAATATATCAAATAAAGCCAGCATTACTACTAGTTTTTCGTTAGTAAATCAAGA
       N  T  N  I  S  N  K  A  S  I  T  T  S  F  S  L  V  N  Q  D

 481  TGGAAATACAGTAAATAGTCAAGATTTTTTGGGAAAATACATGCTAGTTTTATTTGGATT
       G  N  T  V  N  S  Q  D  F  L  G  K  Y  M  L  V  L  F  G  F

 541  TTCTTCATGTAAAAGCATCTGCCCTGCTGAATTAGGAATAGCATCTGAAGTTCTCTCACA
       S  S  C  K  S  I  C  P  A  E  L  G  I  A  S  E  V  L  S  Q

 601  GCTTGGTAATGACACAGACAAGTTACAAGTAATTTTCATTACAATTGATCCAACAAATGA
       L  G  N  D  T  D  K  L  Q  V  I  F  I  T  I  D  P  T  N  D

 661  TACTGTACAAAAATTAAAAACATTTCATGAACATTTTGATCCTAGAATTCAAATGCTAAC
       T  V  Q  K  L  K  T  F  H  E  H  F  D  P  R  I  Q  M  L  T

 721  AGGCAGTGCAGAAGATATTGAAAAAATAATAAAAAATTACAAAATATATGTTGGACAAGC
       G  S  A  E  D  I  E  K  I  I  K  N  Y  K  I  Y  V  G  Q  A

 781  AGATAAAGATAATCAAATTGATCACTCTGCCATAATGTACATTATCGATAAAAAAGGAGA
       D  K  D  N  Q  I  D  H  S  A  I  M  Y  I  I  D  K  K  G  E

 841  ATACATTTCACACTTTTCTCCAGATTTAAAATCAACAGAAAATCAAGTAGATAAGTTACT
       Y  I  S  H  F  S  P  D  L  K  S  T  E  N  Q  V  D  K  L  L

 901  ATCTATAATAAAACAATATCTCTAAtttaataattaattaAAGAGaatagtacacaCTCT
       S  I  I  K  Q  Y  L  *

 961  Tatataaattcatggatatatgtgatgggtagatttcttttggtgtttctatcgctaatt
1021  acatta
```

FIG. 3B

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/US 97/19044

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/29 C12N15/86 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MCGUIRE T. C. ET AL.,: "Recombinant vaccinia virus expression of anaplasma marginale surface protein MSP-1a:effect of promoters, leader sequences and GPI anchor sequence on antibody response" VACCINE, vol. 12, no. 5, - 1994 pages 465-471, XP002057342	1,2,6,7, 10,11
Y	see the whole document	3,4,12, 13,16

Y	OBERLE S. M. & BARBET A.F.: "Derivation of the complete msp4 gene sequence of anaplasma marginale without cloning" GENE, vol. 136, - 1993 pages 291-294, XP002057343 see whole document; esp. p293, par. d ff	3,4,12, 13,16

	-/--	

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
2 March 1998	19. 03. 1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Müller, F

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/US 97/19044

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 90 12030 A (UNIV WASHINGTON) 18 October 1990 see whole doc, esp. claims 61-63 ---	1,2
X	VAN VLIET A.H.M. ET AL.,: "Molecular cloning, sequence analysis and expression of the gene encoding the immunodominant 32-kilodalton protein of cowdria ruminantium" INFECT. AND IMMUNITY, vol. 62, no. 4, - April 1994 pages 1451-1456, XP002057344 see the whole document -----	1,2,10, 11,19

1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No
PCT/US 97/ 19044

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 10-18
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 10-18 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte[illegible]onal Application No
PCT/US 97/19044

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9012030 A	18-10-90	AU 5521490 A	05-11-90
		EP 0467972 A	29-01-92
		JP 4504422 T	06-08-92
		US 5549898 A	27-08-96